{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:23:05Z","timestamp":1738819385868,"version":"3.37.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clinthera.2024.11.023","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:02:56Z","timestamp":1734393776000},"page":"e27-e33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Tolerability of Home Infusions in Down Syndrome Regression Disorder"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-8234","authenticated-orcid":false,"given":"Jonathan D.","family":"Santoro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole A.","family":"Nishimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin N.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie K.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia","family":"Kazerooni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shermila","family":"Pia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mellad M.","family":"Khoshnood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Jafarpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.11.023_bib0001","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-2939","article-title":"Down syndrome disintegrative disorder: a clinical regression syndrome of increasing importance","volume":"145","author":"Rosso","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0002","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/brainsci11091197","article-title":"A systematic review of unexplained early regression in adolescents and adults with Down syndrome","volume":"11","author":"Walpert","year":"2021","journal-title":"Brain Sci"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0003","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/brainsci7060057","article-title":"Acute regression in young people with Down syndrome","volume":"7","author":"Mircher","year":"2017","journal-title":"Brain Sci"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0004","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/ajmg.a.62922","article-title":"Unexplained regression in Down syndrome: management of 51 patients in an international patient database","volume":"188","author":"Santoro","year":"2022","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0005","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/0883073814554654","article-title":"Down syndrome disintegrative disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with Down syndrome","volume":"30","author":"Worley","year":"2015","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s11689-022-09446-w","article-title":"Evidence of neuroinflammation and immunotherapy responsiveness in individuals with Down syndrome regression disorder","volume":"14","author":"Santoro","year":"2022","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0007","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/NDT.S77307","article-title":"Catatonia in Down syndrome; a treatable cause of regression","volume":"11","author":"Ghaziuddin","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0008","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2147\/NDT.S210613","article-title":"Catatonia in Down syndrome: systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients","volume":"15","author":"Miles","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0009","doi-asserted-by":"crossref","first-page":"e63524","DOI":"10.1002\/ajmg.a.63524","article-title":"Safety and tolerability of intravenous immunoglobulin infusion in Down syndrome regression disorder","volume":"194","author":"Santoro","year":"2024","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0010","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41398-023-02579-z","article-title":"Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder","volume":"13","author":"Santoro","year":"2023","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0011","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/acn3.52023","article-title":"Neuroimaging abnormalities associated with immunotherapy responsiveness in Down syndrome regression disorder","volume":"11","author":"Santoro","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/CND.0000000000000201","article-title":"A retrospective analysis of the safety profile of intravenous immunoglobulin in 1176 patients receiving home infusion therapy","volume":"19","author":"Souayah","year":"2018","journal-title":"J Clin Neuromuscul Dis"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2024.11.023_bib0014","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/CND.0b013e3182212589","article-title":"The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders","volume":"12","author":"Souayah","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/CND.0b013e31818b2aef","article-title":"Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions","volume":"10","author":"Rigas","year":"2008","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8147251","article-title":"Safety of intravenous immunoglobulin (Tegeline\u00ae), administered at home in patients with autoimmune disease: results of a French study","volume":"2018","author":"Hachulla","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.940175","article-title":"Assessment and diagnosis of Down syndrome regression disorder: international expert consensus","volume":"13","author":"Santoro","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0018","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s10875-023-01507-6","article-title":"Quality of life evaluation in Saudi Arabian pediatric patients with primary immunodeficiency diseases receiving 20% subcutaneous IgG infusions at home","volume":"43","author":"Al-Saud","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0019","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/ped.14119","article-title":"The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents\u2019 \/caregivers\u2019 satisfaction","volume":"62","author":"Lechanska-Helman","year":"2020","journal-title":"Pediatr Int"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/aur.1906","article-title":"A pilot study of high-dose intravenous immunoglobulin 5% for autism: impact on autism spectrum and markers of neuroinflammation","volume":"11","author":"Melamed","year":"2018","journal-title":"Autism Res"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0021","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1490","article-title":"Subacute neuropsychiatric syndrome in girls with SHANK3 mutations responds to immunomodulation","volume":"145","author":"Bey","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.707463","article-title":"Efficacy, safety and tolerability of a new 10% intravenous immunoglobulin for the treatment of primary immunodeficiencies","volume":"12","author":"Perez","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0023","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/dmcn.13349","article-title":"Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders","volume":"59","author":"Gadian","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s11689-019-9306-9","article-title":"Health comorbidities and cognitive abilities across the lifespan in Down syndrome","volume":"12","author":"Startin","year":"2020","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12016-024-08996-2","article-title":"Down syndrome and autoimmune disease","volume":"66","author":"Hom","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0026","doi-asserted-by":"crossref","first-page":"86","DOI":"10.17294\/2330-0698.1824","article-title":"Prevalence of common disease conditions in a large cohort of individuals with Down syndrome in the United States","volume":"8","author":"Chicoine","year":"2021","journal-title":"J Patient Cent Res Rev"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0027","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1001\/jama.2023.22924","article-title":"Down syndrome in a new era for Alzheimer disease","volume":"330","author":"Rafii","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0028","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0029","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0030","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamaneurol.2024.2579","article-title":"Lecanemab and vascular-amyloid deposition in brains of people with Down syndrome","volume":"81","author":"Liu","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2023.06.021","article-title":"Home versus outpatient hospital intravenous immunoglobulin infusion and health care resource utilization","volume":"63","author":"Rastegar","year":"2023","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0032","first-page":"512","article-title":"Home infusion therapy: comparison of costs for intravenous immunoglobulin","volume":"90","author":"Bielory","year":"1993","journal-title":"N J Med"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0033","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10875-018-0566-z","article-title":"Home-based treatment with immunoglobulins: an evaluation from the perspective of patients and healthcare professionals","volume":"38","author":"Zuizewind","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.clinthera.2024.11.023_bib0034","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10875-017-0371-0","article-title":"Impact of site of care on infection rates among patients with primary immunodeficiency diseases receiving intravenous immunoglobulin therapy","volume":"37","author":"Wasserman","year":"2017","journal-title":"J Clin Immunol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T14:48:27Z","timestamp":1738766907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824003710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0149291824003710"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.11.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Tolerability of Home Infusions in Down Syndrome Regression Disorder","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}